Cardiovascular Diseases among Patients with Cancer and Patients living with HIV

癌症患者和艾滋病毒感染者的心血管疾病

基本信息

批准号：
10546509
负责人：
Tomas G Neilan
金额：
$ 12.31万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-01-02 至 2024-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10546509
关键词：
Address Anthracycline Area Award Biological Markers Blood Cardiac Cardiology Cardiotoxicity Cardiovascular Diseases Cardiovascular system Charge Clinical Clinical Investigator Clinical Research Dedications Development Echocardiography Educational process of instructing Environment Faculty Fatty acid glycerol esters Fibrosis Foundations Funding Future General Hospitals Goals Grant HIV Heart failure Image Imaging Techniques Immune checkpoint inhibitor Immunosuppression Incidence Institution International Leadership Left Ventricular Ejection Fraction Magnetic Resonance Magnetic Resonance Imaging Malignant - descriptor Malignant Neoplasms Manuscripts Massachusetts Medicine Mentors Mentorship Mid-Career Clinical Scientist Award (K24)Multi-Institutional Clinical Trial Myocardial Myocarditis Outcome Outcomes Research PET/CT scan Patient-Focused Outcomes Patients Peer Review Peer Review Grants Persons Positioning Attribute Publications Publishing Radiology Specialty Randomized Registries Research Research Peer Review Research Personnel Research Project Grants Research Support Risk Risk Factors Role Serum Site Structure Testing Time Toxic effect Training Training Programs Training and Education Translational Research Treatment Failure Troponin United States National Institutes of Health atorvastatin attenuation cancer therapy cardiac magnetic resonance imaging cardiovascular imaging career chemotherapy coronary fibrosis experience heart function heart imaging heart preservation improved innovation insight medical schools mid-career faculty mortality novel oncology program patient oriented research preservation programs randomized trial randomized, clinical trials risk stratification side effect skills stem synergism training opportunity treatment and outcome treatment effect

项目摘要

Project Summary/Abstract: Tomas Neilan MD MPH is a clinically-active cardiologist in the Division of Cardiology and Cardiovascular Imaging at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Over the last 10 years, Dr. Neilan’s research has focused on applying advanced imaging to two complementary areas, the cardiovascular toxicities associated with cancer therapies and heart failure among persons with HIV. Dr. Neilan’s extensive mentoring experience, publication and funding record, together with his current and planned research support, demonstrate his commitment and passion for POR and provide an excellent foundation to accomplish the goals and objectives of the K24 Award. The specific aims addressing the purpose of the K24 Award are: 1) To enable Dr. Neilan to dedicate 25% of his time to mentor junior clinical investigators based on already NIH funded projects; 2) To mentor junior clinical investigators from the T-32 program and the pool of residents, fellows, and junior faculty in Cardiology and Radiology with the goal to develop them into clinical researchers who can successfully compete for peer reviewed grants; and 3) To enable Dr. Neilan to consolidate a POR that combines innovative translational, clinical, and outcomes research in cardiovascular imaging and that provides an ideal environment to develop future leaders in clinical research. Dr. Neilan’s current leadership roles align well with this proposal. He is the Co-Director of the Cardiac MR CT PET Program, a clinical research program in cardiovascular imaging supported by the Division of Cardiology and the Department of Radiology, the Associate Director of the MGH T32 training grant in cardiovascular imaging, and the Director of the Cardio-Oncology Program in the Division of Cardiology. In addition to his roles, Dr. Neilan also has an unreserved commitment from the leadership of both Cardiology and Radiology providing a foundation that is ideal to successfully mentor junior clinical investigators and fulfill the purpose of the Award. The specific research aims of this grant stem from a significant body of work accomplished over the past few years and are all based on on-going NIH funded projects, except Aim 4 which is new research specifically supported by this grant: 1) STOP-CA – Testing in a randomized multicenter clinical trial the effect of statins on the reduction in left ventricular ejection fraction after anthracycline-based chemotherapy, 2) REPRIEVE-MR – Testing in a randomized multicenter clinical trial whether statins reduce myocardial fibrosis, myocardial steatosis and preserve cardiac function among persons living with HIV, 3) STOP-CA Fibrosis – where we apply novel MRI- based imaging techniques to provide insight into the role of myocardial fibrosis in the development of anthracycline-induced cardiotoxicity, and test the effect of statins on myocardial fibrosis after anthracyclines, and 4) Expanding our international registry to improve our limited understanding of the predictors, presentation, treatments and outcomes of patients presenting with myocarditis after immune checkpoint inhibitors (ICI’s).

项目摘要/摘要：Tomas Neilan MD MPH 是一位临床活跃的心脏病专家。马萨诸塞州总医院心脏病学和心血管影像学副教授哈佛医学院的医学在过去 10 年里，内兰博士的研究重点是应用。对两个互补领域的先进成像，即与癌症治疗相关的心血管毒性 Neilan 博士拥有丰富的指导经验、出版物和经验。资助记录以及他当前和计划的研究支持表明了他的承诺和对 POR 的热情，为实现 K24 奖的目的和目标提供了良好的基础。 K24 奖的具体目标是： 1) 让 Neilan 博士能够贡献 25% 的资金他根据 NIH 资助的项目指导初级临床研究人员的时间 2) 指导初级临床研究人员；来自 T-32 计划的临床研究人员以及心脏病学领域的住院医生、研究员和初级教员和放射学，目标是将他们培养成能够成功竞争同行的临床研究人员审查拨款；以及 3) 使 Neilan 博士能够巩固结合创新转化、心血管成像的临床和结果研究，并提供了理想的开发环境 Neilan 博士目前的领导角色与这一提议非常吻合。心脏 MR CT PET 项目联席主任，该项目是心血管成像的临床研究项目得到麻省总医院心脏病科和放射科副主任的支持 T32 心血管影像培训补助金，以及该科心脏肿瘤项目主任除了他的职责外，Neilan 博士还得到了领导层的毫无保留的承诺。心脏病学和放射学为成功指导初级临床提供了理想的基础调查人员并实现该奖项的目的该资助的具体研究目标源于一个过去几年中完成的重要工作都是基于 NIH 持续资助的项目，除目标 4 外，该目标是本次拨款特别支持的新研究： 1) STOP-CA – 在随机多中心临床试验中测试他汀类药物对左心室减少的影响蒽环类化疗后的心室射血分数，2) REPRIEVE-MR – 在他汀类药物能否减少心肌纤维化、心肌脂肪变性和心肌梗死的随机多中心临床试验保护 HIV 感染者的心脏功能，3) STOP-CA 纤维化 – 我们应用新型 MRI- 基于成像技术来深入了解心肌纤维化在心肌纤维化发展中的作用蒽环类药物引起的心脏毒性，并测试他汀类药物对蒽环类药物后心肌纤维化的影响， 4) 扩大我们的国际登记册，以提高我们对预测因素、表述、免疫检查点抑制剂（ICI）后出现心肌炎的患者的治疗和结果。